BEAM

Beam Therapeutics
BEAM

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$1.93B
EV
$1.24B
Shares Outstanding
97.26M
Beta
2.02

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$47.87
P/E 2025E
-
P/Revenue 2025E
30.34x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Beam Therapeutics Inc.

gainify
BEAM

Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-30...

Sector

Healthcare

Industry

Biotechnology

CEO

Evans, John

Employees

483

Website

beamtx.com

IPO Date

2020-02-06

Headquarters

238 Main Street, 9th Floor, Cambridge, Massachusetts, 02142-1016, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved